United Asset Strategies’s Bio-Rad Laboratories Class A BIO Stock Holding History

United Asset Strategies’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-500	Closed	-$322K	–	209
2021 Q2	$322K	Sell	500 -100	-17%	-$60.9K	0.04%	173
2021 Q1	$343K	Sell	600 -130	-18%	-$77K	0.05%	168
2020 Q4	$426K	Hold	730	–	–	0.07%	151
2020 Q3	$376K	Hold	730	–	–	0.07%	154
2020 Q2	$330K	Hold	730	–	–	0.07%	146
2020 Q1	$256K	Sell	730 -120	-14%	-$44.1K	0.06%	154
2019 Q4	$315K	Hold	850	–	–	0.06%	168
2019 Q3	$283K	Hold	850	–	–	0.06%	156
2019 Q2	$266K	Sell	850 -500	-37%	-$150K	0.06%	162
2019 Q1	$413K	Sell	1,350 -50	-4%	-$13.5K	0.1%	152
2018 Q4	$325K	Hold	1,400	–	–	0.09%	149
2018 Q3	$438K	Sell	1,400 -25	-2%	-$7.76K	0.1%	149
2018 Q2	$411K	Hold	1,425	–	–	0.11%	157
2018 Q1	$356K	Hold	1,425	–	–	0.11%	154
2017 Q4	$340K	Buy	+1,425	New	+$345K	0.09%	154

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

United Asset Strategies's BIO Position: Q3 2021 in Review

United Asset Strategies sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2021, closing a stake of 500 shares — an estimated $322K sold.

United Asset Strategies first reported a position in BIO in Q4 2017 and held it in 15 quarters. The position peaked at $438K in Q3 2018. 507 funds tracked by Wall St. Rank hold BIO as of Q3 2021.

United Asset Strategies reported no remaining Bio-Rad Laboratories Class A position as of Q3 2021 after selling out during the quarter.
United Asset Strategies sold 500 Bio-Rad Laboratories Class A shares in Q3 2021, an estimated $322K.
United Asset Strategies first reported a position in Bio-Rad Laboratories Class A in Q4 2017 and held it in 15 quarters.
United Asset Strategies's Bio-Rad Laboratories Class A position peaked at $438K in Q3 2018.
507 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2021.

Based on United Asset Strategies's 13F filing for Q3 2021, filed 21 Oct 2021.